Needs of ALS Patients With C9orf72 Mutation and Their Caregivers

Recruiting Observational Study
Amyotrophic Lateral Sclerosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
208 (estimated)
Sponsor
Istituto Auxologico Italiano · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Individuals with Amyotrophic Lateral Sclerosis (ALS) carrying the C9orf72 HRE mutation (C9Pos) often exhibit different phenotypic traits compared to other patients (C9Neg), presenting a more aggressive form of the disease, with also a higher frequency of comorbidity with frontotemporal dementia (ALS-FTD) and a greater prevalence of family history of ALS and/or other neurodegenerative diseases. Co…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
ALS Patients: Inclusion Criteria: * Diagnosis of ALS with mutation C9orf72 (C9Pos) * Age 18 years or older * Fluency in Italian language * Ability to understand the nature of the study and to reply to the questions in the online survey * Informed consent signed Exclusion Criteria: * Clinically r…
Contacts

Vincenzo Silani, Prof.

+3902619111

vincenzo.silani@unimi.it

CONTACT

Luca Grappiolo

+3902619111

luca.grappiolo@auxologico.it

CONTACT